Assess the consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza vaccine (GSK1562902A) in adults aged between 18 and 60 years.
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2016
At a glance
- Drugs AS03A; Influenza A virus vaccine-H5N1
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 10 Nov 2011 Actual end date (June 2008) added as reported by ClinicalTrials.gov
- 29 Sep 2011 NCT00449670 reports patients number as 1181.
- 27 Oct 2008 Actual end date changed from Jun 2008 to Jul 2007 as reported by Clinicaltrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History